Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis

References

• January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–e76.
   PubMed Web of Science ®Google Scholar
• Shea JB, Sears SF. Cardiology patient pages. A patient's guide to living with atrial fibrillation. Circulation. 2008;117(20):e340–e343.
   PubMed Web of Science ®Google Scholar
• Marinigh R, Lip GYH, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56(11):827–837.
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–125.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Kirkwood G, Visweswariah R, et al. How does chronic atrial fibrillation influence mortality in the modern treatment era? Curr Cardiol Rev. 2015;11(3):190–198.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Heidbuchel H. The significance of drug-drug and drug-food interactions of oral anticoagulation. Arrhythm Electrophysiol Rev. 2018;7(1):55–61.
   PubMed Web of Science ®Google Scholar
• Melamed OC, Horowitz G, Elhayany A, et al. Quality of anticoagulation control among patients with atrial fibrillation. Am J Manag Care. 2011;17(3):232–237.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–2037.
   PubMed Web of Science ®Google Scholar
• Helgason CM, Do MA, Nutescu E. Warfarin in patients with stroke and reasons for discontinuation. J Stroke Cerebrovasc Dis. 2004;13(2):70–73.
   PubMedGoogle Scholar
• Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(6):624–631.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Willey V, Franchino-Elder J, Fu A-C, et al. Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population. BMJ Open. 2018;8(6):e020676.
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Esteve-Pastor MA, Roldán V, et al. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. Expert Opin Drug Saf. 2017;16(9):1051–1062.
   PubMed Web of Science ®Google Scholar
• Lowres N, Giskes K, Hespe C, et al. Reducing stroke risk in atrial fibrillation: adherence to guidelines has improved, but patient persistence with anticoagulant therapy remains suboptimal. Korean Circ J. 2019; 49(10):883–907.
   PubMed Web of Science ®Google Scholar
• Kaatz Scott. Core elements of anticoagulation stewardship program. Federal Drug Administration. 2019. https://www.fda.gov/media/132114/download#:∼:text=The%20Core%20Elements%20of%20the,be%20applied%20across%20care%20settings.
   Google Scholar
• Ozaki AF, Choi AS, Te QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2020;13(3):e005969.
   PubMed Web of Science ®Google Scholar
• Raparelli V, Proietti M, Cangemi R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulantsThromb Haemost. 2017;117(2):209–218.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
   PubMed Web of Science ®Google Scholar
• Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 2014;4(6):e004301–e004301.
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919
   PubMed Web of Science ®Google Scholar
• Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36–44.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
   PubMed Web of Science ®Google Scholar
• Puhan MA, Schünemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
   PubMed Web of Science ®Google Scholar
• Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312–324.
   PubMed Web of Science ®Google Scholar
• Baujat B, Mahé C, Pignon JP, et al. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21(18):2641–2652.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–171.
   PubMed Web of Science ®Google Scholar
• Al-Khalili F, Lindström C, Benson L. The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic. Curr Med Res Opin. 2016;32(4):779–785.
   PubMed Web of Science ®Google Scholar
• Annavarapu S, Gandhi P, Li Y, et al. Retrospective Cohort Study to assess the differences in persistence between dabigatran and warfarin in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23(3a):S72.
   Google Scholar
• Annavarapu S, Gandhi PK, Li Y, et al. Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation. J Comp Eff Res. 2018;7(7):685–691.
   PubMed Web of Science ®Google Scholar
• Baker CL, Dhamane AD, Mardekian J, et al. Comparison of drug switching and discontinuation rates in patients with nonvalvular atrial fibrillation treated with different direct oral anticoagulants in the US. Circulation. 2018;138:A14947.
   Google Scholar
• Bancroft T, Lim J, Wang C, et al. Health care resource utilization, costs, and persistence in patients newly diagnosed as having nonvalvular atrial fibrillation and newly treated with dabigatran versus warfarin in the United States. Clin Ther. 2016;38(3):545–556.e6.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150–1157.
   PubMed Web of Science ®Google Scholar
• Cataldo N, Pegoraro V, Ripellino C, et al. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation. Recenti Prog Med. 2018;109(2):113–121.
   PubMedGoogle Scholar
• Coleman CI, Muralikrishna T, Evers T. Treatment persistence and discontinuation with rivaroxaban, dabigatran, and warfarin for stroke prevention in patients with non-valvular atrial fibrillation in the United States. PLoS One. 2016;11(6):e0157769
   PubMed Web of Science ®Google Scholar
• Collings SL, Lefèvre C, Johnson ME, et al. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: a cohort study using primary care data in Germany. PLoS One. 2017;12(10):e0185642
   PubMed Web of Science ®Google Scholar
• Collings SL, Vannier-Moreau V, Johnson ME, et al. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: a cohort study in primary care in France. Arch Cardiovasc Dis. 2018;111(5):370–379.
   PubMed Web of Science ®Google Scholar
• Forslund T, Wettermark B, Hjemdahl P. Atrial fibrillation and persistence with anticoagulant treatment. Circulation. 2015;132(suppl_3):A13898.
   Google Scholar
• Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72(3):329–338.
   PubMed Web of Science ®Google Scholar
• Geng YP, Lan DH, Liu N, et al. Patient-reported treatment satisfaction with dabigatran versus warfarin in patients with non-valvular atrial fibrillation in China. Thromb Haemost. 2018;118(10):1815–1822.
   PubMed Web of Science ®Google Scholar
• Graham S, Raluy-Callado M, Donaldson R, et al. PCV116 – discontinuation and health care resource utilisation in non-valvular atrial fibrillation patients treated with apixaban or warfarin in England. Value Health. 2018;21(3):S112.
   Google Scholar
• Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017;103(17):1331–1338. Sep 1
   PubMed Web of Science ®Google Scholar
• Jackson LR, Kim S, Shrader P, et al. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018;46(4):435–439.
   PubMed Web of Science ®Google Scholar
• Johnson ME, Lefèvre C, Collings SL, et al. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open. 2016;6(9):e011471
   PubMed Web of Science ®Google Scholar
• Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30(7):1317–1325.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non‐valvular atrial fibrillation: contemporary findings in real‐life Danish patients. JAHA. 2017;6(2):e004517.
   Google Scholar
• Larsen TB, Gorst-Rasmussen A, Hvilsted L, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127(7):650–656.e5.
   PubMed Web of Science ®Google Scholar
• Lau WCY, Esther WC, Wong ICK. Persistence of dabigatran versus warfarin therapy in patients with non-valvular atrial fibrillation in the real-world clinical practice. Pharmacoepidemiol Drug Saf. 2015;24(S1):669.
   PubMedGoogle Scholar
• Lau WCY, Li X, Wong ICK, et al. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin. J Thromb Haemost. 2017;15(10):1923–1933.
   PubMed Web of Science ®Google Scholar
• Lefevre C, Johnson ME, Collings SL, et al. Changes over time in treatment persistence of oral anticoagulants in patients with non-valvular atrial fibrillation. J Am Coll Cardiol. 2016;67(13):769.
   Web of Science ®Google Scholar
• Lip GYH, Pan X, Kamble S, et al. Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: apixaban, warfarin, dabigatran, or rivaroxaban. PLoS One. 2018;13(4):e0195950.
   PubMed Web of Science ®Google Scholar
• Manzoor BS, Walton SM, Sharp LK, et al. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. J Thromb Thrombolysis. 2017;44(4):435–441.
   PubMed Web of Science ®Google Scholar
• Maura G, Pariente A, Alla F, et al. Comparison of One-Year Non-Persistence Rates with Dabigatran or Rivaroxaban Versus Vitamin K Antagonists in Newly Treated Atrial Fibrillation Patients: A Competing Risk Analysis in the French Nationwide Healthcare Databases. Pharmacoepidemiol Drug Saf. 2017;26:257–257.
   Google Scholar
• Maura G, Billionnet C, Alla F, et al. Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the French National Health Care databases. Pharmacotherapy. 2018;38(1):6–18.
   PubMed Web of Science ®Google Scholar
• McHorney CA, Ashton V, Laliberté F, et al. Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation. JMCP. 2017;23(9):980–988.
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30(12):2461–2469.
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Thomson E, et al. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2015;31(10):1831–1840.
   PubMed Web of Science ®Google Scholar
• Ramagopalan SV, Graham S, Carroll R, et al. Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin. J Comp Eff Res. 2019;8(6):371–379.
   PubMed Web of Science ®Google Scholar
• Reichman M, et al. Patterns of drug use by initiators of dabigatran and warfarin: uptake and persistence: 141. Pharmacoepidemiol Drug Saf. 2014;21(141):68–69.
   Google Scholar
• Simons LA, Ortiz M, Freedman B, et al. Improved persistence with non-vitamin-K oral anticoagulants compared with warfarin in patients with atrial fibrillation: recent Australian experience. Curr Med Res Opin. 2016;32(11):1857–1861.
   PubMed Web of Science ®Google Scholar
• Song X, Gandhi P, Gilligan AM, et al. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):213–222.
   PubMed Web of Science ®Google Scholar
• Sørensen R, Pallisgaard JL, Nielsen BJ, et al. Persistence with non-vitamin k oral anticoagulants and vitamin k antagonists treatment: a nationwide study of Danish patients with non-valvular atrial fibrillation. Circulation. 2016;134:A17731.
   Web of Science ®Google Scholar
• Sørensen R, Nielsen BJ, Pallisgaard JL, et al. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists. Eur Heart J Cardiovasc Pharmacother. 2017;3(3):151–156.
   PubMed Web of Science ®Google Scholar
• Obamiro KO, Chalmers L, Bereznicki LRE. A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation. Am J Cardiovasc Drugs. 2016;16(5):349–363.
   PubMed Web of Science ®Google Scholar
• Schaefer JK, McBane RD, Wysokinski WE. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol. 2016;95(3):437–449.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–e88. 2016
   PubMed Web of Science ®Google Scholar
• Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence. 2010;4:51–60.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47.
   PubMed Web of Science ®Google Scholar
• Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190–1196.
   PubMed Web of Science ®Google Scholar
• Komócsi A. Discontinuation of anticoagulant treatment: from clinical trials to medication persistence. Curr Med Res Opin. 2015;31(10):1841–1844.
   PubMed Web of Science ®Google Scholar